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clarithromycin, tacrolimus, and glucocorticoidsDear Editor,
A 43-year-old woman was admitted to our department with
a 2-week history of arthralgia, dyspnea, and lower-limb
edema. Finally, she was diagnosed with systemic lupus er-
ythematosus based on arthritis, pleuritis/pericarditis, pro-
teinuria/hematuria, and positive results of antinuclear
antibodies/antidouble strand DNA antibodies. Proteinuria
was 20.6 g/day. She was treated with methylprednisolone
(methyl PSL: 1 g/day for 3 days) and subsequently PSL
(60 mg/day). The pericardial effusion improved; however,
the pleural effusion and proteinuria did not. She was
treated again with methyl PSL (1 g/day for 3 days) and
subsequently with PSL (60 mg/day). The pleural effusion
improved and the proteinuria decreased to 6.78 g/day. The
PSL dosage was gradually decreased. When the PSL dosage
was 40 mg/day and proteinuria decreased to 4.56 g/day, a
renal biopsy was performed and the results were compat-
ible with lupus nephritis (LN) (Class IV). Tacrolimus (TAC,
2 mg/day) was added to PSL (40 mg/day). The trough levels
of TAC proved to be <2.0 ng/mL; therefore, the TAC dosage
was increased to 3 mg/day. When the PSL dosage was
decreased to 30 mg/day, she was discharged. Two weeks
after initiating PSL (30 mg/day) treatment, the urine pro-
tein/urine creatinine ratio (UPCR), which indicates daily
proteinuria, decreased to 4.02 g/gCr. The PSL dosage was
then decreased to 25 mg/day. Four weeks after the PSL
(25 mg/day) treatment, the UPCR further decreased to
2.89 g/gCr. However, the PSL dosage was then unsuccess-
fully decreased to 22.5 mg/day as the UPCR deteriorated.
The PSL dosage was increased again to 25 mg/day, and
UPCR was maintained at approximately 2.4 g/gCr.
Throughout the above-mentioned clinical course, hematu-
ria continued. Because the trough levels of TAC (3 mg/day)
were low (2.5 ng/mL), clarithromycin (600 mg/day), which
is known to raise TAC blood concentrations [1,2], was
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maturia gradually improved. The PSL dosage could be
decreased again. Eight weeks after the clarithromycin
treatment, the UPCR decreased to 0.85 g/gCr and the he-
maturia disappeared on PSL (22.5 mg/day). The PSL dosage
was then gradually decreased to 10 mg/day, and UPCR was
maintained at approximately 0.3 g/gCr without recurrent
hematuria. It was recently reported that TAC may be a
reasonable alternative to cyclophosphamide in the induc-
tion of treatment for active LN [3]. We regarded the
optimal trough levels of TAC as 6.0e8.0 ng/mL, according
to the TAC target concentration of LN [4]. Because the
trough levels of TAC (3 mg/day) were low, clarithromycin
was successfully added. TAC is an immunosuppressant
agent that is primarily metabolized by cytochrome P450
(CYP) 3A4 [1,2]. When TAC is orally administered, blood
concentrations vary widely between individuals and are
genetically affected [5]. Clarithromycin is a potent CYP3A4
inhibitor [1,2]. Therefore, clarithromycin suppressed TAC
metabolism by inhibiting CYP3A4, and the trough levels of
TAC increased.
This allowed disease activity to be controlled by optimal
TAC concentrations. Therefore, clarithromycin may be a
useful drug for LN when optimal levels of TAC are difficult
to achieve.
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